Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 14Carcinoma, Non-Small-Cell Lung 13Neoplasms 10Glioblastoma 9Fallopian Tube Neoplasms 8Colorectal Neoplasms 8Breast Neoplasms 8Lung Neoplasms 7Rectal Neoplasms 6Neoplasm Metastasis 6Gliosarcoma 6Colonic Neoplasms 6Carcinoma, Renal Cell 6Brain Neoplasms 6Prostatic Neoplasms 4Melanoma 4Uterine Cervical Neoplasms 3Solitary Fibrous Tumor, Pleural 3Sarcoma, Alveolar Soft Part 3Sarcoma 3Mesothelioma, Malignant 3Carcinoma, Hepatocellular 3Breast Neoplasms, Male 3Advanced Solid Tumor 3Uveal Melanoma 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Pancreatic Neoplasms 2Oligodendroglioma 2Leukemia, Myeloid, Acute 2

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Fallopian Tube Mucinous Adenocarcinoma × cediranib × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡